

Pilot Cohort Analysis (First 10 Patients)

Generated on: September 24, 2025 at 12:22 AM

Executive Summary

Metric	Value
Total Patients	10
Patients with Survival Data	9
Mean Overall Survival (days)	702.4
Progression Rate	50.0%
Overall Response Rate	0.0%

Survival Analysis

Survival Metric	Mean (days)	Median (days)	Sample Size
Overall Survival	702.4	689.0	9
Time to Progression	543.4	517.0	5
Progression-Free Survival	615.8	626.0	9

Key Findings:

- 10 of 10 patients are alive
- 5 patients have experienced progression
- Progression rate: 50.0%

Treatment Response Analysis


No treatment response data available.

Molecular Marker Correlations

Biomarker	Category	Count	Percentage
IDH Status	Wildtype	8	88.9%
IDH Status	Unknown	1	11.1%

MGMT Status	Unmethylated	5	55.6%
MGMT Status	Methylated	3	33.3%
MGMT Status	Unknown	1	11.1%

Statistical Visualizations



Patient Cohort Details

Test Patient (MRN: TEST001)

DOB: 1970-01-01

Diagnosis Date: Not recorded

Primary Location: Not recorded

Jill Reed (MRN: MRN000001)

DOB: 1945-09-26

Diagnosis Date: 2023-06-04

Primary Location: Left temporal lobe

Thomas Anderson (MRN: MRN000002)

DOB: 1996-01-05

Diagnosis Date: 2024-05-17

Primary Location: Cerebellum

Jason Rodriguez (MRN: MRN000003)

DOB: 2000-09-22

Diagnosis Date: 2025-03-24

Primary Location: Right occipital lobe

Jonathan Murphy (MRN: MRN000004)

DOB: 1995-01-11

Diagnosis Date: 2023-11-12

Primary Location: Right fronto-parietal

James Davis (MRN: MRN000005)

DOB: 1998-02-24

Diagnosis Date: 2022-10-10

Primary Location: Corpus callosum

Paul Smith (MRN: MRN000006)

DOB: 1990-11-10

Diagnosis Date: 2023-03-25

Primary Location: Right fronto-parietal

Jose Myers (MRN: MRN000007)

DOB: 1996-08-05

Diagnosis Date: 2024-12-12

Primary Location: Left frontal lobe

Olivia Williams (MRN: MRN000008)

DOB: 1995-04-10

Diagnosis Date: 2024-05-03

Primary Location: Right occipital lobe

Nicholas Carpenter (MRN: MRN000009)

DOB: 1997-02-16

Diagnosis Date: 2024-09-04

Primary Location: Right occipital lobe

Methodology and Notes

Data Analysis Methodology:

- Survival metrics calculated from diagnosis date to last follow-up or event
- Time-to-progression defined as time from diagnosis to first progressive disease
- Treatment response assessed using RECIST criteria when available
- Molecular markers analyzed for correlation with clinical outcomes
- Statistical calculations performed using standard clinical research methods

Limitations:

- Analysis based on available data; missing data may affect results
- Follow-up times may vary between patients
- Treatment response assessment dependent on imaging availability

Generated by: GBM Tracker Advanced Analytics Engine

Report Date: September 24, 2025